Taking on-board the Alexion acquisition
21/07/21 -"AstraZeneca has completed the acquisition of Alexion Pharmaceuticals (US rare diseases specialist). Given that rare diseases are a high-growth and attractive margin area (even ahead of oncology), ..."
Pages
70
Language
English
Published on
21/07/21
You may also be interested by these reports :
30/07/26
Ipsen demonstrated robust performance in Q2, exceeding market expectations, which led to an upgraded 2026 guidance. While we may adjust our estimates ...
30/07/26
Bachem released its 1H26 results on 30 July 2026, delivering a strong operating performance for the half. Margins were affected by higher operating ...
29/07/26
The Q2 profitability was somewhat ahead of consensus, and the firm maintained its full-year guidance. Improving profitability and free cash flows, ...
28/07/26
The Q2 results were ahead of expectations, backed by strong growth across GSK’s key focus areas. The management maintained its full-year guidance. ...